Alcon, a global eye care company, is set to purchase Israel-based Belkin Vision, producer of the Eagle laser for glaucoma, in a deal worth up to $446 million.
The deal to acquire Belkin Vision will reportedly involve an initial upfront transfer of $81 million, including about $65 million in cash.
Belkin Vision’s technology is known as direct selective laser trabeculoplasty (DSLT). DSLT is an automated procedure that aims to help lower a patient’s intraocular pressure without medications or eyedrops, where untreated increases can cause damage to the optic nerve.
Sean Clark, President, Global Surgical Franchise, Alcon, commented: "As a therapy with significant advantages for the patient and practice, we believe our newly acquired DSLT technology is uniquely positioned to accelerate the evolution toward first-line use of selective laser trabeculoplasty (SLT) in the glaucoma treatment paradigm. We look forward to broadening access to this exciting technology in the future as we continue to address solutions for unmet needs in glaucoma.”
Beyond the initiation payments, there is an opportunity for an additional $385 million in sales-based milestone payments if Alcon can secure the technology as clinicians’ go-to option in first-line therapy.
As well as the DSLT technology, Alcon also offers implantable technology such as its Hydrus Microstent.
